【摘要】 目的:观察吉西他滨联合奥沙利铂治疗中晚期原发性肝癌(PLC)的疗效和安全性。方法:入组本研究的36例中晚期PLC患者接受了吉西他滨联合奥沙利铂方案治疗:吉西他滨1 000mg/m2,第1,8天,奥沙利铂130mg/m2,第1天,每3周重复。使用RECIST 1.0标准评价近期疗效和NCI-CTC 3.0版评价不良反应。结果:所有病例均可评价疗效和不良反应,36例患者共计接受化疗161个周期(4.5周期/例),获得部分缓解6例(16.7%),稳定16例(44.4%),疾病控制率为61.1%,进展14例(38.9%),无病例获得完全缓解;全组病例中位生存时间(mOS)为10.8个月,其中疾病获得控制的病例组的mOS为12.8个月,明显优于疾病进展病例组的4.6个月(P<0.01)。Ⅲ~Ⅳ度血液学毒性方面,白细胞减少发生率为18.6%,血小板减少发生率为11.1%。非血液学毒性反应轻微。结论:吉西他滨联合奥沙利铂治疗中晚期PLC具有良好的疗效,病人耐受性较好。更多还原

【Abstract】 Objective:To evaluate the efficacy and safety of gemcitabine combined with oxaliplatin(GEMOX)in treatment of patients with advanced primary liver cancer(PLC).Methods:Thirty-six patients with advanced PLC were enrolled in the study and received the GEMOX regimen with gemcitabine 1000mg/m2 on days 1and 8,and oxaliplatin 130mg/m2 on day 1.The treatment was repeated every 3weeks.The RECIST 1.0and NCI-CTC 3.0was used to evaluate the effects and the toxicity,respectively.Results:All patients were assessable for efficacy and toxicity.A total of 161 treatment cycles were administered.Six patients(16.7%)had partial response,16patients(44.4%)had stable disease,and the disease control rates(DCR)was 61.1%,14patients(38.9%)achieved disease progression,no complete remission cases.The median overall survival times(mOS)was 10.8months of all patients,meanwhile,the mOS of disease control group was better than that of disease progression group(12.8months vs.4.6months,P <0.01).Grade 3-4hematological toxicity included leucopenia(18.6%)and thrombocytopenia(11.1%). Nonhematologic toxicity was mild.Conclusion:The combination of gemcitabine and oxaliplatin in treatment of advanced primary liver carcinoma was effective and well tolerated.更多还原